{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:26:38Z","timestamp":1784366798588,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-024-04103-6","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T11:10:34Z","timestamp":1734779434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A novel conditioning regimen with pre-transplantation immunosuppression reduces the complication rates in hematopoietic stem cell transplantation in transfusion-dependent \u03b2-thalassemia"],"prefix":"10.1186","volume":"15","author":[{"given":"Huaqing","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Que","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaofen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiawei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengzhou","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danping","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honggui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianpei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"issue":"3","key":"4103_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul H, et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and \u03b2-Thalassemia. N Engl J Med. 2021;384(3):252\u201360.","journal-title":"N Engl J Med"},{"issue":"8","key":"4103_CR2","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/s41591-022-01906-z","volume":"28","author":"B Fu","year":"2022","unstructured":"Fu B, et al. CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric \u03b2(0)\/\u03b2(0) transfusion-dependent \u03b2-thalassemia. Nat Med. 2022;28(8):1573\u201380.","journal-title":"Nat Med"},{"issue":"6","key":"4103_CR3","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.bbmt.2020.01.002","volume":"26","author":"U Anurathapan","year":"2020","unstructured":"Anurathapan U, et al. Hematopoietic Stem Cell Transplantation for Severe Thalassemia Patients from Haploidentical Donors Using a Novel Conditioning Regimen. Biol Blood Marrow Transpl. 2020;26(6):1106\u201312.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"4103_CR4","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1016\/j.bbmt.2014.07.016","volume":"20","author":"U Anurathapan","year":"2014","unstructured":"Anurathapan U, et al. Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification. Biol Blood Marrow Transpl. 2014;20(12):2066\u201371.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"4103_CR5","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/bmt.2016.7","volume":"51","author":"U Anurathapan","year":"2016","unstructured":"Anurathapan U, et al. Hematopoietic stem cell transplantation for homozygous \u03b2-thalassemia and \u03b2-thalassemia\/hemoglobin E patients from haploidentical donors. Bone Marrow Transpl. 2016;51(6):813\u20138.","journal-title":"Bone Marrow Transpl"},{"issue":"23","key":"4103_CR6","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1182\/blood-2016-06-724005","volume":"128","author":"C de Koning","year":"2016","unstructured":"de Koning C, Nierkens S, Boelens JJ. Strategies before, during, and after hematopoietic cell transplantation to improve T-cell immune reconstitution. Blood. 2016;128(23):2607\u201315.","journal-title":"Blood"},{"issue":"6","key":"4103_CR7","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.21037\/tp-20-415","volume":"10","author":"C Huang","year":"2021","unstructured":"Huang C, et al. Hematopoietic stem cell transplantation for thalassemia major using HLA fully-matched and mismatched donor grafts. Transl Pediatr. 2021;10(6):1552\u201365.","journal-title":"Transl Pediatr"},{"issue":"Suppl 2","key":"4103_CR8","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41409-019-0598-x","volume":"54","author":"L Oevermann","year":"2019","unstructured":"Oevermann L, et al. HLA-haploidentical hematopoietic stem cell transplantation in pediatric patients with hemoglobinopathies: current practice and new approaches. Bone Marrow Transpl. 2019;54(Suppl 2):743\u20138.","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"4103_CR9","doi-asserted-by":"publisher","first-page":"e27026","DOI":"10.1002\/pbc.27026","volume":"65","author":"K Huang","year":"2018","unstructured":"Huang K, et al. Modified conditioning regimen improves outcomes of unrelated donor peripheral blood stem cell transplantation for \u03b2-thalassaemia major patients. Pediatr Blood Cancer. 2018;65(7):e27026.","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"4103_CR10","doi-asserted-by":"publisher","first-page":"e13876","DOI":"10.1111\/petr.13876","volume":"24","author":"H Chen","year":"2020","unstructured":"Chen H, et al. Prediction, management, and prognosis of mixed chimerism after hematopoietic stem cell transplantation in transfusion-dependent pediatric thalassemia patients. Pediatr Transpl. 2020;24(8):e13876.","journal-title":"Pediatr Transpl"},{"issue":"5","key":"4103_CR11","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1182\/blood.V87.5.2082.2082","volume":"87","author":"G Lucarelli","year":"1996","unstructured":"Lucarelli G, et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood. 1996;87(5):2082\u20138.","journal-title":"Blood"},{"issue":"3","key":"4103_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/bjh.18520","volume":"200","author":"J Hu","year":"2023","unstructured":"Hu J, et al. Haploidentical transplant for paediatric patients with severe thalassaemia using post-transplant cyclophosphamide and methotrexate: A prospectively registered multicentre trial from the Bone Marrow Failure Working Group of Hunan Province, China. Br J Haematol. 2023;200(3):329\u201337.","journal-title":"Br J Haematol"},{"issue":"7","key":"4103_CR13","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s41409-024-02257-8","volume":"59","author":"S Furst","year":"2024","unstructured":"Furst S, et al. Durable engraftment after pharmacological pre-transplant immune suppression followed by reduced-toxicity myeloablative haploidentical stem cell transplantation in highly HLA-immunized adults with sickle cell disease. Bone Marrow Transpl. 2024;59(7):918\u201327.","journal-title":"Bone Marrow Transpl"},{"issue":"19","key":"4103_CR14","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1182\/blood-2012-03-417998","volume":"120","author":"C Li","year":"2012","unstructured":"Li C, et al. A novel conditioning regimen improves outcomes in \u03b2-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation. Blood. 2012;120(19):3875\u201381.","journal-title":"Blood"},{"issue":"3","key":"4103_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s12185-014-1510-5","volume":"99","author":"Y Jiang","year":"2014","unstructured":"Jiang Y, et al. Chimerism status is correlated to acute graft-versus-host disease after allogeneic stem cell transplantation. Int J Hematol. 2014;99(3):323\u20138.","journal-title":"Int J Hematol"},{"key":"4103_CR16","unstructured":"Przepiorka D et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant, 1995;15(6):825-8."},{"issue":"3","key":"4103_CR17","first-page":"247","volume":"4","author":"K Atkinson","year":"1989","unstructured":"Atkinson K, et al. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transpl. 1989;4(3):247\u201354.","journal-title":"Bone Marrow Transpl"},{"issue":"20","key":"4103_CR18","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"issue":"6","key":"4103_CR19","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.bbmt.2006.01.009","volume":"12","author":"J Ayello","year":"2006","unstructured":"Ayello J, et al. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering. Biol Blood Marrow Transpl. 2006;12(6):608\u201322.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"4103_CR20","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.bbmt.2007.05.004","volume":"13","author":"V Mathews","year":"2007","unstructured":"Mathews V, et al. A new stratification strategy that identifies a subset of class III patients with an adverse prognosis among children with beta thalassemia major undergoing a matched related allogeneic stem cell transplantation. Biol Blood Marrow Transpl. 2007;13(8):889\u201394.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"4103_CR21","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1182\/blood-2010-09-306829","volume":"117","author":"M Sabloff","year":"2011","unstructured":"Sabloff M, et al. HLA-matched sibling bone marrow transplantation for \u03b2-thalassemia major. Blood. 2011;117(5):1745\u201350.","journal-title":"Blood"},{"issue":"5","key":"4103_CR22","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41409-022-01613-w","volume":"57","author":"MA Yesilipek","year":"2022","unstructured":"Yesilipek MA, et al. Thalassemia-free and graft-versus-host-free survival: outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience. Bone Marrow Transpl. 2022;57(5):760\u20137.","journal-title":"Bone Marrow Transpl"},{"issue":"17","key":"4103_CR23","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1182\/bloodadvances.2019000291","volume":"3","author":"C Li","year":"2019","unstructured":"Li C, et al. Related and unrelated donor transplantation for beta-thalassemia major: results of an international survey. Blood Adv. 2019;3(17):2562\u201370.","journal-title":"Blood Adv"},{"issue":"7","key":"4103_CR24","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.bbmt.2020.03.016","volume":"26","author":"VV Swaminathan","year":"2020","unstructured":"Swaminathan VV, et al. Matched Family versus Alternative Donor Hematopoietic Stem Cell Transplantation for Patients with Thalassemia Major: Experience from a Tertiary Referral Center in South India. Biol Blood Marrow Transpl. 2020;26(7):1326\u201331.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"4103_CR25","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.hoc.2022.12.009","volume":"37","author":"M Algeri","year":"2023","unstructured":"Algeri M, Lodi M, Locatelli F. Hematopoietic Stem Cell Transplantation in Thalassemia. Hematol Oncol Clin North Am. 2023;37(2):413\u201332.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"8","key":"4103_CR26","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/s41409-018-0427-7","volume":"54","author":"M Lv","year":"2019","unstructured":"Lv M, et al. Class I and II human leukocyte antibodies in pediatric haploidentical allograft candidates: prevalence and risk factors. Bone Marrow Transpl. 2019;54(8):1287\u201394.","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"4103_CR27","doi-asserted-by":"publisher","first-page":"e14648","DOI":"10.1111\/petr.14648","volume":"28","author":"B Malbora","year":"2024","unstructured":"Malbora B, et al. Effect of serum panel reactive antibodies on allogeneic hematopoietic stem cell transplantation in pediatric thalassemia patients: A single-center experience. Pediatr Transpl. 2024;28(1):e14648.","journal-title":"Pediatr Transpl"},{"issue":"5","key":"4103_CR28","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1080\/08880010902976098","volume":"26","author":"JP Fang","year":"2009","unstructured":"Fang JP, et al. Panel reactive antibody in thalassemic serum inhibits proliferation and differentiation of cord blood CD34\u2009+\u2009cells in vitro. Pediatr Hematol Oncol. 2009;26(5):338\u201344.","journal-title":"Pediatr Hematol Oncol"},{"issue":"10","key":"4103_CR29","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.exphem.2012.06.003","volume":"40","author":"M Detrait","year":"2012","unstructured":"Detrait M, et al. Impact of anti-HLA antibodies on allogeneic hematopoietic stem cell transplantation outcomes after reduced-intensity conditioning regimens. Exp Hematol. 2012;40(10):792\u20139.","journal-title":"Exp Hematol"},{"issue":"4","key":"4103_CR30","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/7445","volume":"5","author":"DA Frank","year":"1999","unstructured":"Frank DA, Mahajan S, Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med. 1999;5(4):444\u20137.","journal-title":"Nat Med"},{"issue":"1","key":"4103_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40425-018-0371-5","volume":"6","author":"AJ Giles","year":"2018","unstructured":"Giles AJ, et al. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018;6(1):51.","journal-title":"J Immunother Cancer"},{"key":"4103_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-015-0182-9","volume":"8","author":"YJ Chang","year":"2015","unstructured":"Chang YJ, et al. Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. J Hematol Oncol. 2015;8:84.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"4103_CR33","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","volume":"55","author":"A Spyridonidis","year":"2020","unstructured":"Spyridonidis A, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transpl. 2020;55(6):1114\u201325.","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"4103_CR34","doi-asserted-by":"publisher","first-page":"E297","DOI":"10.1002\/ajh.25969","volume":"95","author":"Y He","year":"2020","unstructured":"He Y, et al. Long-term results of the NF-08-TM protocol in stem cell transplant for patients with thalassemia major: A multi-center large-sample study. Am J Hematol. 2020;95(11):E297\u20139.","journal-title":"Am J Hematol"},{"key":"4103_CR35","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.lfs.2018.12.018","volume":"218","author":"A Iqubal","year":"2019","unstructured":"Iqubal A, et al. Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision. Life Sci. 2019;218:112\u201331.","journal-title":"Life Sci"},{"issue":"5","key":"4103_CR36","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/pedi.13260","volume":"23","author":"L Zhang","year":"2022","unstructured":"Zhang L, et al. Indicators of glucose dysregulation and the relationship with iron overload in Chinese children with beta thalassemia major. Pediatr Diabetes. 2022;23(5):562\u20138.","journal-title":"Pediatr Diabetes"},{"issue":"5","key":"4103_CR37","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.fertnstert.2020.11.040","volume":"115","author":"D Shai","year":"2021","unstructured":"Shai D, et al. Ovaries of patients recently treated with alkylating agent chemotherapy indicate the presence of acute follicle activation, elucidating its role among other proposed mechanisms of follicle loss. Fertil Steril. 2021;115(5):1239\u201349.","journal-title":"Fertil Steril"},{"issue":"8","key":"4103_CR38","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/molehr\/gaz020","volume":"25","author":"QN Nguyen","year":"2019","unstructured":"Nguyen QN, et al. Cisplatin- and cyclophosphamide-induced primordial follicle depletion is caused by direct damage to oocytes. Mol Hum Reprod. 2019;25(8):433\u201344.","journal-title":"Mol Hum Reprod"}],"container-title":["Stem Cell Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-024-04103-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-024-04103-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-024-04103-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T12:04:03Z","timestamp":1734782643000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-024-04103-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4103"],"URL":"https:\/\/doi.org\/10.1186\/s13287-024-04103-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5148087\/v1","asserted-by":"object"}]},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,21]]},"assertion":[{"value":"27 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research protocol \u2018The Impact of Modified Pretreatment Scheme on the Efficacy of Hematopoietic Stem Cell Transplantation for Treatment of Thalassemia\u2019 was approved by the Ethics Committee of Sun Yat-sen Memorial Hospital of Sun Yat-sen University (SYSKY-2023-425-01) on 11 May 2023. Informed consent was obtained from all participants and the parents\/guardians of the children under 18 years of age. This study was conducted in accordance with the Declaration of Helsinki. The protocol, amendments, and informed consent forms were approved by the appropriate institutional review board and independent ethics committee before the study began. Written informed consent was obtained from all patients prior to enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and connect to participate"}},{"value":"The authors have declared that no conflicts of interest. No financial or non-financial benefits have been received or will be received from any party directly or indirectly related to the subject of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"495"}}